Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal)

Draft guidance: 1

Draft consultation document (downloadable version) (PDF 296 KB)

Committee papers (PDF 8.46 MB)

Presentation Slides redacted (PowerPoint 627 KB)

Equality impact assessment (downloadable version) (PDF 129 KB)

Final scope (PDF 185 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 231 KB)

Equality impact assessment (Scoping) (PDF 126 KB)

Draft scope post referral (PDF 201 KB)